First Header Logo Second Header Logo

Caio Max S. Rocha Lima MD, MS

TitleProfessor
InstitutionWake Forest School of Medicine
DepartmentInternal Medicine, Hematology & Oncology
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kim R, Chiorean EG, Amin M, Rocha-Lima CMS, Gandhi J, Harris WP, Song T, Portnoy D. Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment. Br J Cancer. 2017 Jul 11; 117(2):189-194. PMID: 28632730.
      Citations:    
    2. Narayanan G, Hosein PJ, Beulaygue IC, Froud T, Scheffer HJ, Venkat SR, Echenique AM, Hevert EC, Livingstone AS, Rocha-Lima CM, Merchan JR, Levi JU, Yrizarry JM, Lencioni R. Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. J Vasc Interv Radiol. 2017 Mar; 28(3):342-348. PMID: 27993507.
      Citations:    
    3. Montero AJ, Kwon D, Flores A, Kovacs K, Trent JC, Benedetto P, Rocha-Lima C, Merchan JR. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 07 01; 22(13):3209-17. PMID: 26864210.
      Citations:    
    4. Khushman M, Dempsey N, Maldonado JC, Loaiza-Bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-Cordovi J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CW, Merchan JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, Portelance L, Sleeman D, Levi JU, Lima CM, Hosein PJ. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology. 2015 Nov-Dec; 15(6):667-73. PMID: 26412296.
      Citations:    
    5. Socola F, Nguyen DM, Ochoa RE, Rocha Lima CM, Hosein PJ. A cohort study evaluating the role of surgery for lung metastases from colorectal cancer. Anticancer Res. 2015 Jun; 35(6):3431-5. PMID: 26026106.
      Citations:    
    6. Bhatia SS, Venkat S, Echenique A, Rocha-Lima C, Doshi MH, Salsamendi J, Barbery K, Narayanan G. Proximal Splenic Artery Embolization in Chemotherapy-Induced Thrombocytopenia: A Retrospective Analysis of 13 Patients. J Vasc Interv Radiol. 2015 Aug; 26(8):1205-11. PMID: 25990134.
      Citations:    
    7. Kim Y, Shaffer KM, Rocha-Lima C, Milton A, Carver CS. Exploring the role of ethnicity on perceptions of cancer and physical health recovery during the first year of survivorship. J Health Psychol. 2016 07; 21(7):1331-8. PMID: 25293968.
      Citations:    
    8. Rocha-Lima CM, de Queiroz Marques Junior E, Bayraktar S, Broome P, Weissman C, Nowacki M, Leslie M, Susnerwala S. A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan. Cancer Chemother Pharmacol. 2014 Sep; 74(3):479-86. PMID: 25030089.
      Citations:    
    9. Cleary JM, Lima CM, Hurwitz HI, Montero AJ, Franklin C, Yang J, Graham A, Busman T, Mabry M, Holen K, Shapiro GI, Uronis H. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs. 2014 Oct; 32(5):937-45. PMID: 24916770.
      Citations:    
    10. Hosein PJ, Echenique A, Loaiza-Bonilla A, Froud T, Barbery K, Rocha Lima CM, Yrizarry JM, Narayanan G. Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system. J Vasc Interv Radiol. 2014 Aug; 25(8):1233-1239.e2. PMID: 24861662.
      Citations:    
    11. Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol. 2014 Apr; 73(4):839-45. PMID: 24562589.
      Citations:    
    12. Palacio S, Loaiza-Bonilla A, Kittaneh M, Kyriakopoulos C, Ochoa RE, Escobar M, Arango B, Restrepo MH, Merchan JR, Rocha Lima CM, Hosein PJ. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer. Anticancer Res. 2014 Jan; 34(1):301-6. PMID: 24403478.
      Citations:    
    13. Bayraktar UD, Warsch S, Chen E, Lima CM, Pereira D. Comparison of cancer care and outcomes between a public safety-net hospital and a private cancer center. J Health Care Poor Underserved. 2013 Aug; 24(3):1136-49. PMID: 23974387.
      Citations:    
    14. Bayraktar S, Rocha-Lima CM. Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World J Clin Oncol. 2013 May 10; 4(2):29-42. PMID: 23696960.
      Citations:    
    15. Hosein PJ, de Lima Lopes G, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol. 2013 Apr; 36(2):151-6. PMID: 22307213.
      Citations:    
    16. Liu-Mares W, Mackinnon JA, Sherman R, Fleming LE, Rocha-Lima C, Hu JJ, Lee DJ. Pancreatic cancer clusters and arsenic-contaminated drinking water wells in Florida. BMC Cancer. 2013 Mar 12; 13:111. PMID: 23510413.
      Citations:    
    17. Wolpin BM, O'Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla T, McWhirter E, Pezet D, Lichinitser M, Roman L, Hartford A, Morrison K, Jackson L, Vincent M, Reyno L, Hidalgo M. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013 Jul; 24(7):1792-1801. PMID: 23448807.
      Citations:    
    18. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Feb; 71(2):523-30. PMID: 23228990.
      Citations:    
    19. Narayanan G, Hosein PJ, Arora G, Barbery KJ, Froud T, Livingstone AS, Franceschi D, Rocha Lima CM, Yrizarry J. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol. 2012 Dec; 23(12):1613-21. PMID: 23177107.
      Citations:    
    20. Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013 Jan; 17(1):94-100; discussion p. 100-1. PMID: 23229886.
      Citations:    
    21. Bayraktar S, Rocha Lima CM. Emerging cell-cycle inhibitors for pancreatic cancer therapy. Expert Opin Emerg Drugs. 2012 Dec; 17(4):571-82. PMID: 23126234.
      Citations:    
    22. Rocha Lima CM, Bayraktar S, Flores AM, MacIntyre J, Montero A, Baranda JC, Wallmark J, Portera C, Raja R, Stern H, Royer-Joo S, Amler LC. Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Cancer Invest. 2012 Dec; 30(10):727-31. PMID: 23061802.
      Citations:    
    23. Merchan JR, Ferrell A, Macintyre J, Ciombor KK, Levi J, Ribeiro A, Sleeman D, Flores A, Lopes G, Rocha-Lima CM. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Am J Clin Oncol. 2012 Oct; 35(5):446-50. PMID: 21552097.
      Citations:    
    24. Rocha Lima CM, Lin EH, Kim GP, Giguere JK, Marshall J, Zalupski M, Papageorgio C, Auber ML, Kaleta R, McHenry MB, Trifan OC, Philip PA. A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. Gastrointest Cancer Res. 2012 Sep; 5(5):155-60. PMID: 23112883.
      Citations:    
    25. Kurian S, Macintyre J, Mushtaq M, Rocha-Lima CM, Ahn Y. Oxaliplatin induced disseminated intravascular coagulation: A case report and review of literature. World J Gastrointest Oncol. 2012 Jul 15; 4(7):181-3. PMID: 22844549.
      Citations:    
    26. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E, Fuchs CS. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012 Nov; 23(11):2834-2842. PMID: 22700995.
      Citations:    
    27. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012 May 29; 12:199. PMID: 22642850.
      Citations:    
    28. Ochoa R, Sudhindra A, Garcia-Buitrago M, Romilly AP, Cortes J, Gomez H, Rocha Lima CM, Silva O. Small-cell cancer of the breast: what is the optimal treatment? A report and review of outcomes. Clin Breast Cancer. 2012 Aug; 12(4):287-92. PMID: 22520734.
      Citations:    
    29. Rocha-Lima CM, Bayraktar S, Macintyre J, Raez L, Flores AM, Ferrell A, Rubin EH, Poplin EA, Tan AR, Lucarelli A, Zojwalla N. A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors. Cancer. 2012 Sep 01; 118(17):4262-70. PMID: 22294459.
      Citations:    
    30. Kim Y, Carver CS, Rocha-Lima C, Shaffer KM. Depressive symptoms among caregivers of colorectal cancer patients during the first year since diagnosis: a longitudinal investigation. Psychooncology. 2013 Feb; 22(2):362-7. PMID: 22109965.
      Citations:    
    31. Bayraktar UD, Bayraktar S, Hosein P, Chen E, Koniaris LG, Rocha-Lima CM, Montero AJ. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. Med Oncol. 2012 Sep; 29(3):1707-10. PMID: 22033912.
      Citations:    
    32. Kubiliun N, Ribeiro A, Fan YS, Rocha-Lima CM, Sleeman D, Merchan J, Barkin J, Levi J. EUS-FNA with rescue fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results. Gastrointest Endosc. 2011 Sep; 74(3):541-7. PMID: 21752364.
      Citations:    
    33. Fabregas J, Talebi TN, Rocha Lima C, Sfakianakis GN, Robinson P, Montero AJ. Patient with synchronous low grade leiomyosarcoma of the thigh, primary pancreatic neuroendocrine tumor, and lung metastases: Why biopsy of metastases should be the standard. J Gastrointest Oncol. 2011 Jun; 2(2):109-12. PMID: 22811838.
      Citations:    
    34. Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten DS. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer. 2011 Jun 28; 105(1):44-52. PMID: 21629245.
      Citations:    
    35. Ascunce G, Ribeiro A, Reis I, Rocha-Lima C, Sleeman D, Merchan J, Levi J. EUS visualization and direct celiac ganglia neurolysis predicts better pain relief in patients with pancreatic malignancy (with video). Gastrointest Endosc. 2011 Feb; 73(2):267-74. PMID: 21295640.
      Citations:    
    36. Bayraktar UD, Chen E, Bayraktar S, Sands LR, Marchetti F, Montero AJ, Rocha-Lima CM. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? Cancer. 2011 Jun 01; 117(11):2364-70. PMID: 24048783.
      Citations:    
    37. Bayraktar S, Rocha-Lima CM. Advanced or metastatic pancreatic cancer: molecular targeted therapies. Mt Sinai J Med. 2010 Nov-Dec; 77(6):606-19. PMID: 21105124.
      Citations:    
    38. Carrion AF, Hosein PJ, Cooper EM, Lopes G, Pelaez L, Rocha-Lima CM. Severe colitis associated with docetaxel use: A report of four cases. World J Gastrointest Oncol. 2010 Oct 15; 2(10):390-4. PMID: 21160890.
      Citations:    
    39. Ramachandran K, Miller H, Gordian E, Rocha-Lima C, Singal R. Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity. Anticancer Res. 2010 Oct; 30(10):3919-25. PMID: 21036703.
      Citations:    
    40. Bayraktar S, Bayraktar UD, Rocha-Lima CM. Timing of adjuvant and neoadjuvant therapy in colorectal cancers. Clin Colorectal Cancer. 2010 Jul; 9(3):144-9. PMID: 20643618.
      Citations:    
    41. Bayraktar UD, Bayraktar S, Rocha-Lima CM. Molecular basis and management of gastrointestinal stromal tumors. World J Gastroenterol. 2010 Jun 14; 16(22):2726-34. PMID: 20533592.
      Citations:    
    42. Burris HA, Rosen LS, Rocha-Lima CM, Marshall J, Jones S, Cohen RB, Kunkel LA, Loo D, Baughman J, Stewart SJ, Lewis N. Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. Clin Cancer Res. 2010 Mar 01; 16(5):1673-81. PMID: 20179219.
      Citations:    
    43. Bayraktar S, Bayraktar UD, Rocha-Lima CM. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol. 2010 Feb 14; 16(6):673-82. PMID: 20135714.
      Citations:    
    44. Ascunce G, Ribeiro A, Rocha-Lima C, Larsen M, Sleeman D, Merchan J, Szabo D, Levi JU. Single-session endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography for evaluation of pancreaticobiliary disorders. Surg Endosc. 2010 Jun; 24(6):1447-50. PMID: 20054580.
      Citations:    
    45. Rocha-Lima CM, Raez LE. Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. P T. 2009 Oct; 34(10):554-64. PMID: 20140116.
      Citations:    
    46. Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Rocha-Lima C, Kelley S, Calvin DP, Yeatman TJ, Begg AC, Torres-Roca JF. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys. 2009 Oct 01; 75(2):489-96. PMID: 19735873.
      Citations:    
    47. Hosein PJ, Rocha-Lima CM. Role of combined-modality therapy in the management of locally advanced rectal cancer. Clin Colorectal Cancer. 2008 Nov; 7(6):369-75. PMID: 19036689.
      Citations:    
    48. Shah SM, Ribeiro A, Levi J, Jorda M, Rocha-Lima C, Sleeman D, Hamilton-Nelson K, Ganjei-Azar P, Barkin J. EUS-guided fine needle aspiration with and without trucut biopsy of pancreatic masses. JOP. 2008 Jul 10; 9(4):422-30. PMID: 18648133.
      Citations:    
    49. Vulfovich M, Rocha-Lima C. Novel advances in pancreatic cancer treatment. Expert Rev Anticancer Ther. 2008 Jun; 8(6):993-1002. PMID: 18533808.
      Citations:    
    50. Rocha-Lima CM. New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs. 2008 Jun; 19(5):435-46. PMID: 18418211.
      Citations:    
    51. Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP, Lenz HJ. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. J Clin Oncol. 2008 May 10; 26(14):2320-6. PMID: 18467723.
      Citations:    
    52. Burris H, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist. 2008 Mar; 13(3):289-98. PMID: 18378539.
      Citations:    
    53. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007 Oct 20; 25(30):4793-9. PMID: 17947727.
      Citations:    
    54. Lopes G, Quesada J, Ahn E, Flores A, Ribeiro A, Rocha-Lima CM. Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual. Clin Colorectal Cancer. 2007 Sep; 6(9):641-5. PMID: 17945036.
      Citations:    
    55. Gutierrez JC, De Oliveira LO, Perez EA, Rocha-Lima C, Livingstone AS, Koniaris LG. Optimizing diagnosis, staging, and management of gastrointestinal stromal tumors. J Am Coll Surg. 2007 Sep; 205(3):479-91 (Quiz 524). PMID: 17765165.
      Citations:    
    56. Miller AA, Wang XF, Bogart JA, Hodgson LD, Rocha Lima CM, Radford JE, Vokes EE, Green MR. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J Thorac Oncol. 2007 Jul; 2(7):645-51. PMID: 17607121.
      Citations:    
    57. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control. 2007 Jul; 14(3):295-304. PMID: 17615536.
      Citations:    
    58. de Lima Lopes G, Rocha Lima CM. Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib. Pharmacotherapy. 2007 May; 27(5):775-7. PMID: 17461715.
      Citations:    
    59. de Lima Lopes G, Chiappori A, Simon G, Haura E, Sullivan D, Antonia S, Langevin M, Lush R, Rocha-Lima CM. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas. Cancer. 2007 Apr 01; 109(7):1413-9. PMID: 17326096.
      Citations:    
    60. Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM, Benson AB. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2007 Feb; 30(1):26-31. PMID: 17278891.
      Citations:    
    61. Perez EA, Gutierrez JC, Jin X, Lee DJ, Rocha-Lima C, Livingstone AS, Franceschi D, Koniaris LG. Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination. J Gastrointest Surg. 2007 Jan; 11(1):114-25. PMID: 17390197.
      Citations:    
    62. Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer. 2006 Dec 01; 107(11):2688-97. PMID: 17075878.
      Citations:    
    63. Rocha-Lima CM, Herndon JE, Lee ME, Atkins JN, Mauer A, Vokes E, Green MR. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol. 2007 Feb; 18(2):331-7. PMID: 17065590.
      Citations:    
    64. Simon GR, Lush RM, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan DM, Munster PN. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. . 2006 Aug; 5(8):2130-7. PMID: 16928835.
      Citations:    
    65. Raez LE, Santos ES, Lopes G, Rosado MF, Negret LM, Rocha-Lima C, Tolba K, Farfan N, Hamilton-Nelson K, Silva O, Roman E. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer. 2006 Sep; 53(3):347-53. PMID: 16844257.
      Citations:    
    66. Storch I, Jorda M, Thurer R, Raez L, Rocha-Lima C, Vernon S, Ribeiro A. Advantage of EUS Trucut biopsy combined with fine-needle aspiration without immediate on-site cytopathologic examination. Gastrointest Endosc. 2006 Oct; 64(4):505-11. PMID: 16996340.
      Citations:    
    67. Khanna A, Walker GR, Livingstone AS, Arheart KL, Rocha-Lima C, Koniaris LG. Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg. 2006 May; 10(5):689-97. PMID: 16713541.
      Citations:    
    68. Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N, Jorda M, Koniaris LG. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg. 2006 Apr; 202(4):623-9. PMID: 16571433.
      Citations:    
    69. Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology. 2005; 68(4-6):382-90. PMID: 16020967.
      Citations:    
    70. Lopes G, Rocha Lima CM. Docetaxel in the management of advanced pancreatic cancer. Semin Oncol. 2005 Apr; 32(2 Suppl 4):S10-23. PMID: 16015551.
      Citations:    
    71. Moulder SL, Mahany JJ, Lush R, Rocha-Lima C, Langevin M, Ferrante KJ, Bartkowski LM, Kajiji SM, Noe DA, Paillet S, Sullivan DM. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res. 2004 Nov 01; 10(21):7127-35. PMID: 15534083.
      Citations:    
    72. Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004 Sep 15; 22(18):3776-83. PMID: 15365074.
      Citations:    
    73. Rocha Lima CM, Catapano CV, Pacheco D, Sherman CA, Oakhill G, Mushtaq C, Freeman KD, Green MR. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors. Cancer. 2004 Jun 15; 100(12):2671-9. PMID: 15197811.
      Citations:    
    74. D'Amato G, Rocha Lima C, Mahany JJ, Muro-Cacho C, Haura EB. Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature. Lung Cancer. 2004 Jun; 44(3):381-90. PMID: 15140552.
      Citations:    
    75. Rocha Lima CM, Rizvi NA, Zhang C, Herndon JE 2nd, Crawford J, Govindan R, King GW, Green MR. Cancer Leukemia Group B. Random Phase II trial of Gemcitabine and docetaxel or Irinotecan and Gemcitabine in advanced or metastatic NSCLC. 2004; 15(3):410-8.
    76. Shoemaker LK, Arora U, Rocha Lima CM. 5-fluorouracil-induced coronary vasospasm. Cancer Control. 2004 Jan-Feb; 11(1):46-9. PMID: 14749623.
      Citations:    
    77. Simon GR, Ruckdeschel JC, Williams C, Cantor A, Chiappori A, Rocha Lima CM, Antonia S, Haura E, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control. 2003 Sep-Oct; 10(5):388-95. PMID: 14581894.
      Citations:    
    78. Bhargava P, Jani CR, Savarese DM, O'Donnell JL, Stuart KE, Rocha Lima CM. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):23-6. PMID: 14569844.
      Citations:    
    79. Rocha Lima CM, Chiappori A. Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan. Lung Cancer. 2003 Jun; 40(3):229-36. PMID: 12781421.
      Citations:    
    80. Coutinho AK, Rocha Lima CM. Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control. 2003 May-Jun; 10(3):224-38. PMID: 12794621.
      Citations:    
    81. Chiappori AA, Rocha-Lima CM. New agents in the treatment of small-cell lung cancer: focus on gemcitabine. Clin Lung Cancer. 2003 Jan; 4 Suppl 2:S56-63. PMID: 14720338.
      Citations:    
    82. Freitas JR, Rocha-Lima CM. Therapy of advanced non-small-cell lung cancer with irinotecan and gemcitabine in combination. Clin Lung Cancer. 2002 Nov; 4 Suppl 1:S26-9. PMID: 14659038.
      Citations:    
    83. Rocha Lima CM, Joppert MG. Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer. Oncology (Williston Park). 2002 Sep; 16(9 Suppl 9):25-31. PMID: 12375798.
      Citations:    
    84. Rocha Lima CM, Centeno B. Update on pancreatic cancer. Curr Opin Oncol. 2002 Jul; 14(4):424-30. PMID: 12130928.
      Citations:    
    85. Rocha Lima CM, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Green MR. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):19-24. PMID: 12109801.
      Citations:    
    86. Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002 Mar 01; 20(5):1182-91. PMID: 11870159.
      Citations:    
    87. Rocha Lima CM, Herndon JE, Kosty M, Clamon G, Green MR. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer. 2002 Jan 01; 94(1):181-7. PMID: 11815975.
      Citations:    
    88. Rocha Lima CM, Urbanic JJ, Lal A, Kneuper-Hall R, Brunson CY, Green MR. Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies. Semin Oncol. 2001 Jun; 28(3 Suppl 10):34-43. PMID: 11510032.
      Citations:    
    89. Rocha Lima CM, Sherman CA, Brescia FJ, Brunson CY, Green MR. Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 5):46-51. PMID: 11301841.
      Citations:    
    90. Rocha Lima CM, Urbanic JJ, Sherman CA, Brescia FJ, Green MR. Docetaxel followed by gemcitabine and irinotecan in solid tumors. Oncology (Williston Park). 2001 Jan; 15(1 Suppl 1):37-45. PMID: 11221020.
      Citations:    
    91. Green MR, Harper M, Safa A, Sherman CA, Mushtaq CM, Bahadori H, Brescia FJ, Rocha Lima CM. Irinotecan in the management of patients with pancreatic cancer. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):31-3. PMID: 11200146.
      Citations:    
    92. Sherman CA, Rocha Lima CM, Turrisi AT. Limited small-cell lung cancer: a potentially curable disease. Oncology (Williston Park). 2000 Oct; 14(10):1395-403; discussion 1403-4, 1409. PMID: 11098505.
      Citations:    
    93. Green MR, Rocha Lima CM, Sherman CA. Radiation and chemotherapy for patients with stage III non-small cell lung cancer. Semin Radiat Oncol. 2000 Oct; 10(4):289-95. PMID: 11040329.
      Citations:    
    94. Cappuzzo F, Rocha Lima CM, Sherman CA, Green MR. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 4):7-14. PMID: 10960939.
      Citations:    
    95. Bahadori HR, Rocha Lima CM, Green MR, Safa AR. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res. 1999 Nov-Dec; 19(6B):5423-8. PMID: 10697572.
      Citations:    
    96. Rocha Lima CM, Eckardt JR, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Bahadori HR, Green MR. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer. Semin Oncol. 1999 Oct; 26(5 Suppl 16):43-50; discussion 71-2. PMID: 10585008.
      Citations:    
    97. Leong SS, Rocha Lima CM, Sherman CA, Green MR. . Staging System for Non-Small Cell Lung Cancer: Some Points for Thought. 1999; 115(1):242-8.
    Rocha Lima's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (292)
    Explore
    _
    Similar People (48)
    Explore
    _
    Same Department Expand Description
    Explore
    _